instruction:
Given a question and a context passage, generate the answer having the word or phrase from the context passage. Here, the answer should be a shortest continous span from the passage.
question:
Context: As of the 2010 United States Census, there were 1,951,269 people, 715,365 households, and 467,916 families residing in the county. The population density was . There were 840,343 housing units at an average density of . The racial makeup of the county was 60.9% white, 10.5% black or African American, 8.7% Asian, 0.7% Pacific islander, 0.7% American Indian, 13.5% from other races, and 5.1% from two or more races. Those of Hispanic or Latino origin made up 29.1% of the population. In terms of ancestry, 11.7% were Germans, 9.1% were Irish people, 7.6% were English people, 6.3% were Italians, and 2.7% were Americans. 
 Question: Which group in percent is smaller for the county according to the census: Germans or Americans?
answer:
americans


question:
Context: On July 15, 2009 Nucleosys was announced to be disbanding. 
 Question: What year was the end of Nucleosys?
answer:
2009


question:
Context: Idarucizumab is a monoclonal antibody fragment specifically targeted to dabigatran. It has demonstrated prompt and durable reversal of the anticoagulant effects of dabigatran in animal studies and phase 1 studies of young, elderly, and renally impaired volunteers. Although elective invasive procedures and most bleeding complications in dabigatran-treated patients can be managed by temporarily stopping dabigatran therapy and using supportive measures, there are rare clinical situations that require urgent reversal of the anticoagulant effect of dabigatran. The effectiveness and safety of 5 g of intravenous idarucizumab is being investigated in a prospective, open-label, single-cohort study in patients with serious bleeding or in those requiring an urgent procedure. In an interim analysis of the first 90 participants, idarucizumab rapidly and completely reversed the anticoagulant activity of dabigatran in 88%-98% of participants, and there were no safety concerns, with no deaths or serious adverse events being attributable to idarucizumab. Supported by these interim results, idarucizumab has been approved in the United States and the European Union for use when reversal of the anticoagulant effects of dabigatran is needed for emergency surgery/urgent procedures or in patients with life-threatening or uncontrolled bleeding. Clinical use of idarucizumab should follow the same processes as patient enrollment in this study, which is projected to be completed in 2016. The outcomes achieved with this specific reversal agent are likely to be of continued interest to treating physicians. 
 Question: Which drug can be reversed with idarucizumab?
answer:

dabigatran